Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy.
Abstract OBJECTIVES: To investigate the impact of the increased use of neoadjuvant chemotherapy on the complexity of cytoreductive surgeries for ovarian cancer. METHODS: Using the National Cancer Database, we performed a retrospective cohort study of women diagnosed between 2004 and 2015 with stage III or IV epithelial ovarian cancer who underwent either primary cytoreductive surgery (PDS) followed by adjuvant chemotherapy, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery. Cases were assigned a surgical complexity category as 1) Inadequate, 2) Low, 3) Moderate and, 4) High complexity. Th...
Source: Gynecologic Oncology - June 11, 2019 Category: Cancer & Oncology Authors: Horner W, Peng K, Pleasant V, Brackmann M, Ebott J, Gutfreund R, McLean K, Reynolds RK, Uppal S Tags: Gynecol Oncol Source Type: research

Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study.
Abstract OBJECTIVE: About 30% of Adult type granulosa cell tumors of the ovary (AGCTs) are diagnosed in fertile age. In stage I, conservative surgery (fertility-sparing surgery, FSS), either unilateral salpingo-oophorectomy (USO) or cystectomy are possible options. The aim of this study is to compare oncological outcomes of FSS and radical surgery (RS) in apparently stage I AGCTs treated within the MITO group (Multicenter Italian Trials in Ovarian cancer). METHODS: Survival curves were calculated using the Kaplan-Meier method and compared with log-rank test. The role of clinicopathological variables as progno...
Source: Gynecologic Oncology - June 10, 2019 Category: Cancer & Oncology Authors: Bergamini A, Cormio G, Ferrandina G, Lorusso D, Giorda G, Scarfone G, Bocciolone L, Raspagliesi F, Tateo S, Cassani C, Savarese A, Breda E, De Giorgi U, Mascilini F, Candiani M, Kardhashi A, Biglia N, Perrone AM, Pignata S, Mangili G Tags: Gynecol Oncol Source Type: research

Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
Abstract OBJECTIVE: To compare referral patterns, genetic testing and pathogenic variant rates in Black women (BW) and White women (WW) in a large academic Gynecologic Cancer Risk Assessment Clinic (GCRAC). METHODS: Cross sectional study of an IRB-approved prospective, cohort study from a GCRAC. Data evaluated included: age, race, referral provider specialty and indication, genetic testing frequency, as well as frequency and types of pathogenic variants. RESULTS: 588 WW and 57 BW were evaluated from 1/2010-12/2015. Although approximately one-third of BW and WW were referred for family history alone, refe...
Source: Gynecologic Oncology - June 10, 2019 Category: Cancer & Oncology Authors: Boitano TKL, Barrington DA, Batra S, McGwin G, Turner TB, Farmer MB, Brown AM, Straughn MJ, Leath CA Tags: Gynecol Oncol Source Type: research

Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis.
CONCLUSIONS: Among HPV positive women of 30 years and older, a negative FAM19A4/miR124-2 methylation triage test provides a similar long-term CIN3+ risk compared with a negative cytology triage test. Because of their high CIN3+ risk, women with a positive methylation triage test could be referred for colposcopy. Therefore, FAM19A4/miR124-2 methylation analysis is a promising alternative to cytology for triage of HPV positive women. PMID: 31182225 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 7, 2019 Category: Cancer & Oncology Authors: Dick S, Kremer WW, De Strooper LMA, Lissenberg-Witte BI, Steenbergen RDM, Meijer CJLM, Berkhof J, Heideman DAM Tags: Gynecol Oncol Source Type: research

Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth.
CONCLUSIONS: MET+SIM treatment synergistically inhibits endometrial cancer cell viability. This may be mediated by apoptosis and mTOR pathway inhibition. Our results provide preclinical evidence that the combination of these well-tolerated drugs may warrant further clinical investigation for endometrial cancer treatment. PMID: 31178149 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 6, 2019 Category: Cancer & Oncology Authors: Kim JS, Turbov J, Rosales R, Thaete LG, Rodriguez GC Tags: Gynecol Oncol Source Type: research

Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer.
CONCLUSION: We observed that women who took certain forms of an AH medication during the year following a diagnosis of ovarian cancer were thereafter at a relatively reduced risk of dying from their disease. However, the potential for residual confounding by disease severity argues for a cautious interpretation. PMID: 31178150 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 6, 2019 Category: Cancer & Oncology Authors: Harding BN, Delaney JA, Urban RR, Weiss NS Tags: Gynecol Oncol Source Type: research

Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women.
Abstract BACKGROUND AND AIM: Age-specific type-distribution of high-risk human papillomavirus (hrHPV) in cervical precancerous lesions is subject to change in the HPV vaccination era. Knowing the pre-vaccination type-distribution helps to anticipate changes induced by mass vaccination and optimize screening. METHODS: We recruited 1279 women referred to colposcopy for abnormal cytology into a population-based study on HPV type distribution in diagnostic cervical samples (ISRCTN10933736). The HPV genotyping findings were grouped as: HPV16/18+, other hrHPV+ (HPV31/33/35/39/45/51/52/56/58/59/66/68), non-vaccine t...
Source: Gynecologic Oncology - June 5, 2019 Category: Cancer & Oncology Authors: Aro K, Nieminen P, Louvanto K, Jakobsson M, Virtanen S, Lehtinen M, Dillner J, Kalliala I Tags: Gynecol Oncol Source Type: research

Long term resource consequences of a nationwide introduction of robotic surgery for women with early stage endometrial cancer.
CONCLUSIONS: The introduction of robotic surgery for early stage endometrial cancer did not generate any long-term cost savings. The additional costs of robotic surgery were primarily driven by the index surgery. Any reduction in bed days could be explained by time trends. PMID: 31176554 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 5, 2019 Category: Cancer & Oncology Authors: Korsholm M, Gyrd-Hansen D, Mogensen O, Möller S, Sopina L, Joergensen SL, Jensen PT Tags: Gynecol Oncol Source Type: research

Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management.
Abstract Immature teratomas (IT) are rare and recurrences uncommon. A 12-year-old female with grade 3 (high-grade) ovarian IT underwent surgical resection but experienced early recurrences; the first was treated with surgery but the second was metastatic and managed with chemotherapy, resulting in growing-teratoma-syndrome and need for further surgery. She now remains well in uneventful clinical follow-up. We believe chemotherapy could be reserved for very carefully selected recurrent IT cases, which may alter the natural history of disease. PMID: 31176555 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 5, 2019 Category: Cancer & Oncology Authors: Frazer JL, Hook CE, Addley HC, Jackson CR, Latimer JA, Nicholson JC, Murray MJ Tags: Gynecol Oncol Source Type: research

A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
CONCLUSIONS: IPA is well tolerated in combination with sequential C/P. ORR, PFS and OS are comparable to historical data but bone toxicity at efficacy doses of this particular Wnt inhibitor limit further development in EOC. PMID: 31174889 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 4, 2019 Category: Cancer & Oncology Authors: Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA, Morgan MA, Kapoun AM, Brachmann RK, Stagg R, Farooki A, O'Cearbhaill RE Tags: Gynecol Oncol Source Type: research

Rates over time and regional variation of radical minimally invasive surgery for cervical cancer: A population based study.
CONCLUSIONS: Although rates of radical MIS increased in Ontario over the time period studied, this seems to have been driven by a few high volume centres. Cervical cancer is rare and it takes time to develop the skills to carry out the procedure effectively. Abandonment of minimally invasive radical hysterectomy may have a significant impact on surgical training and subsequent proficiency in the skills unique to this procedure. PMID: 31171407 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 3, 2019 Category: Cancer & Oncology Authors: Willows K, Kupets R, Diong C, Vicus D, Covens A, Gien LT Tags: Gynecol Oncol Source Type: research

Regionalization of care for women with ovarian cancer.
We examined changes over time in surgeon and hospital procedural volume for ovarian cancer and explored the association between volume and perioperative outcomes. METHODS: The New York Statewide Planning and Research Cooperative System (SPARCS) database was used to examine women with ovarian cancer who underwent surgery from 2000 to 2014. Annualized surgeon and hospital procedural volume were estimated and each grouped into quartiles. Changes over time in the annual number of surgeons and hospitals rendering care were estimated. The association between surgeon and hospital volume and perioperative morbidity and mortal...
Source: Gynecologic Oncology - June 3, 2019 Category: Cancer & Oncology Authors: Wright JD, Chen L, Buskwofie A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Hur C, Neugut AI, Hershman DL Tags: Gynecol Oncol Source Type: research

Role of adjuvant radiation or re-excision for early stage vulvar squamous cell carcinoma with positive or close surgical margins.
This study aims to evaluate whether re-excision or adjuvant radiation for stage I vulvar squamous cell carcinoma (SCC) with either a close or positive surgical margin improves recurrence-free survival. METHODS: Patients with pathologically confirmed FIGO stage I vulvar SCC who underwent primary surgical management between January 1, 1995 and September 30, 2017 and had positive or close (
Source: Gynecologic Oncology - June 3, 2019 Category: Cancer & Oncology Authors: Bedell SM, Hedberg C, Griffin A, Pearson H, Wilhite A, Rubin N, Erickson BK Tags: Gynecol Oncol Source Type: research

ProMisE on the horizon: molecular classification of endometrial cancer in young women.
PMID: 31151551 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 1, 2019 Category: Cancer & Oncology Authors: Wethington SL, Fader AN Tags: Gynecol Oncol Source Type: research

Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.
CONCLUSIONS: Most women with BRCA mutations surviving beyond age 75 received their genetic test result at an older age and had a history of BRCA-related cancer. Women continued surveillance and risk reducing surgeries at an older age. Pancreatic cancer was the most common new cancer diagnosed in older BRCA mutation carriers. PMID: 31160070 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 31, 2019 Category: Cancer & Oncology Authors: Salyer C, Kobelka C, Barrie A, Weintraub MR, Powell CB Tags: Gynecol Oncol Source Type: research

Corrigendum to "Financial toxicity - An overlooked side effect" [Gynecol. Oncol. 150 (2018) 3-6].
Corrigendum to "Financial toxicity - An overlooked side effect" [Gynecol. Oncol. 150 (2018) 3-6]. Gynecol Oncol. 2019 May 31;: Authors: Liang MI, Huh WK PMID: 31160071 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 31, 2019 Category: Cancer & Oncology Authors: Liang MI, Huh WK Tags: Gynecol Oncol Source Type: research

Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look".
CONCLUSIONS: IP port cytology is predictive of recurrence and survival in patients with ovarian cancer. This inexpensive test may serve as an adjunct to imaging and tumor markers to determine disease status at the completion of treatment. Further study should investigate how this may impact management. PMID: 31160072 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 31, 2019 Category: Cancer & Oncology Authors: Grette K, Long B, Finan MA, Rocconi RP Tags: Gynecol Oncol Source Type: research

Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology.
CONCLUSIONS: HPV genotyping identified multiple risk bands for ≥CIN3 and ≥CIN2 in the ≥21 year-old ASC-US and LSIL populations. These results support a 1-year follow-up period to preclude immediate colposcopy for ASC-US or LSIL women positive for the lowest-risk HPV genotypes. PMID: 31160073 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 31, 2019 Category: Cancer & Oncology Authors: Wright TC, Stoler MH, Parvu V, Yanson K, Cooper C, Andrews J Tags: Gynecol Oncol Source Type: research

Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
CONCLUSIONS: After controlling for multiple potential confounders, patients receiving surgery in high volume centers had a higher likelihood of complete gross resection following primary debulking surgery for advanced-stage epithelial ovarian cancer. PMID: 31160074 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 31, 2019 Category: Cancer & Oncology Authors: Nasioudis D, Kahn R, Chapman-Davis E, Frey MK, Caputo TA, Witkin SS, Holcomb K Tags: Gynecol Oncol Source Type: research

Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma.
Abstract OBJECTIVE: Primary mucinous ovarian carcinoma (MOC) is a rare histologic subtype of ovarian cancer. The benefit of adjuvant chemotherapy for patients with MOC is unclear. PATIENTS AND METHODS: Patients diagnosed with stage I mucinous ovarian cancer (MOC) between 2004 and 2015 were identified from the U.S National Cancer Database. Those with a history of another primary tumor were excluded. Factors independently associated with the receipt of chemotherapy were identified using logistic regression. Impact of chemotherapy on overall survival (OS) for patients diagnosed between 2004 and 2014 was assessed...
Source: Gynecologic Oncology - May 30, 2019 Category: Cancer & Oncology Authors: Nasioudis D, Haggerty AF, Giuntoli RL, Burger RA, Morgan MA, Ko EM, Latif NA Tags: Gynecol Oncol Source Type: research

Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis.
Abstract OBJECTIVE: To report population-based statistics of women with uterine cancer and a history of prior breast cancer. METHODS: This is a retrospective study examining the Surveillance, Epidemiology, and End Results Program between 1973 and 2013. Temporal trends, clinico-pathological characteristics, and survival of women with uterine cancer who had prior breast cancer were assessed. RESULTS: Among 237,686 women with uterine cancer, 8235 (3.5%) women had antecedent breast cancer. The number of women with uterine cancer who had a history of breast cancer increased between 1975 and 1989 (21.1-fold re...
Source: Gynecologic Oncology - May 23, 2019 Category: Cancer & Oncology Authors: Matsuo K, Mandelbaum RS, Machida H, Yoshihara K, Muggia FM, Roman LD, Wright JD Tags: Gynecol Oncol Source Type: research

Is immunohistochemistry-based screening for Lynch syndrome in endometrial cancer effective? The consent's the thing.
CONCLUSION: The primary driver of failure to identify index cases remains consent for sequencing. Consent rates have shown little improvement since LS screening programs were instituted in the U.S., leaving us to conclude these high failure rates are resistant to substantial improvement. These missed opportunities will be magnified because cascade screening for carrier status among family members will not be pursued. PMID: 31130287 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 23, 2019 Category: Cancer & Oncology Authors: Gudgeon JM, Varner MW, Hashibe M, Williams MS Tags: Gynecol Oncol Source Type: research

Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
CONCLUSION: Although the objective response rate to anastrozole was relatively low, clinical benefit was observed in 44% of patients with ER/PR positive metastatic endometrial cancer and associated with an improvement in QOL. PMID: 31130288 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 23, 2019 Category: Cancer & Oncology Authors: Mileshkin L, Edmondson R, O'Connell RL, Sjoquist KM, Andrews J, Jyothirmayi R, Beale P, Bonaventura T, Goh J, Hall M, Clamp A, Green J, Lord R, Amant F, Alexander L, Carty K, Paul J, Scurry J, Millan D, Nottley S, Friedlander M, PARAGON study group Tags: Gynecol Oncol Source Type: research

Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer.
CONCLUSIONS: Ultrastaging and pathologic review of negative pelvic lymph nodes of patients with presumed isolated paraaortic metastasis can identify occult pelvic dissemination and reduce the prevalence of true isolated paraaortic disease. In the era of the sentinel lymph node (SLN) algorithm for EC staging, which incorporates ultrastaging of the SLNs removed, these findings demonstrate that use of the SLN algorithm can further mitigate the concern of missing cases of isolated paraaortic dissemination. PMID: 31126637 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 22, 2019 Category: Cancer & Oncology Authors: Multinu F, Casarin J, Cappuccio S, Keeney GL, Glaser GE, Cliby WA, Weaver AL, McGree ME, Angioni S, Faa G, Leitao MM, Abu-Rustum NR, Mariani A Tags: Gynecol Oncol Source Type: research

Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
CONCLUSIONS: The combination of trametinib and GSK2141795 was feasible but required dose holds and modifications for adverse events; however, anti-cancer activity was minimal, even in patients with PI3K or RAS pathway alterations. Although the study was terminated early after GSK2141795 development was halted, the findings in these 14 patients do not support further development of this combination in cervical cancer. PMID: 31118140 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 20, 2019 Category: Cancer & Oncology Authors: Liu JF, Gray KP, Wright AA, Campos S, Konstantinopoulos PA, Peralta A, MacNeill K, Morrissey S, Whalen C, Dillon D, Matulonis UA Tags: Gynecol Oncol Source Type: research

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
dha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF, HGSC CRS Collaborative Network (Supplementary 1), Singh N Abstract OBJECTIVE: There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT. METHODS: We est...
Source: Gynecologic Oncology - May 19, 2019 Category: Cancer & Oncology Authors: Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha Tags: Gynecol Oncol Source Type: research

Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
CONCLUSION: This is the largest study to date comparing outcomes in patients with EOC and BM by mutation status. mBRCA patients were more likely to have isolated BM, which may be a factor in their long survival. This supports the pursuit of aggressive treatment for mBRCA EOC patients with BM. Additional studies examining the correlation of BRCA mutational status with BM are warranted. PMID: 31113680 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 18, 2019 Category: Cancer & Oncology Authors: Stasenko M, Cybulska P, Feit N, Makker V, Konner J, O'Cearbhaill RE, Alektiar KM, Beal K, Gardner GJ, Long Roche KC, Sonoda Y, Chi DS, Zivanovic O, Leitao MM, Cadoo KA, Tew WP Tags: Gynecol Oncol Source Type: research

50th Annual Meeting of the Society of Gynecologic Oncology.
PMID: 31109661 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 18, 2019 Category: Cancer & Oncology Authors: Brown CL Tags: Gynecol Oncol Source Type: research

Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.
Abstract OBJECTIVE: To identify the optimal adjuvant treatment regimen for patients with endometrioid and non-endometrioid node-positive endometrial cancer. METHODS: We retrospectively identified 249 women with FIGO 2009 stage IIIC endometrial cancer at our institution who underwent surgical staging from 1985 to 2015 followed by external beam radiotherapy (RT), chemotherapy (CT), or a combination of CT + RT. Survival rates were calculated using the Kaplan-Meier method. RESULTS: The 5-year disease-specific survival (DSS) rate for all patients was 65%. Adjuvant CT + RT conferred higher rates of 5-y...
Source: Gynecologic Oncology - May 17, 2019 Category: Cancer & Oncology Authors: Chapman BV, Swanick CW, Ning MS, Allen PK, Soliman PT, Westin SN, Pardeshi V, Broaddus RR, Lu KH, Jhingran A, Eifel PJ, Klopp AH Tags: Gynecol Oncol Source Type: research

Margin status revisited in vulvar squamous cell carcinoma.
CONCLUSIONS: Local recurrences frequently occur in patients with primary vulvar carcinoma and are associated with dVIN (with or without LS) in the pathologic margin rather than any tumor free margin distance. Our results should lead to increased awareness among physicians of an ongoing risk for local recurrence and need for life-long follow-up. Intensified follow-up and treatment protocols for patients with dVIN in the margin should be evaluated in future research. PMID: 31109660 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 17, 2019 Category: Cancer & Oncology Authors: Te Grootenhuis NC, Pouwer AW, de Bock GH, Hollema H, Bulten J, van der Zee AGJ, de Hullu JA, Oonk MHM Tags: Gynecol Oncol Source Type: research

Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study.
Abstract AIM: Although obesity has been associated with endometrioid (type I) and, to a lesser extent, with serous (type II) endometrial cancer (EC), the association with the same histotypes of ovarian cancer (OC) remains unclear. Therefore, we intended to compare the role of BMI in carcinogenesis of endometrioid and the serous malignancies, at both ovarian and endometrial level. METHODS: A retrospective case-to-case study was performed in the University Hospital of Bologna (Italy), through the review of primary EC matched with the corresponding OC cases in the same period (1988-2017). RESULTS: We includ...
Source: Gynecologic Oncology - May 16, 2019 Category: Cancer & Oncology Authors: Grandi G, Perrone AM, Chiossi G, Friso S, Toss A, Sammarini M, Facchinetti F, Botticelli L, Palma F, De Iaco P Tags: Gynecol Oncol Source Type: research

Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy.
CONCLUSION: Correlations within and among the instruments indicate EPIC bowel and urinary domains are measuring conceptually discrete components of health. These EPIC domains are valid, reliable and sensitive instruments to measure PRO among women undergoing pelvic radiation. PMID: 31104905 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 16, 2019 Category: Cancer & Oncology Authors: Gil KM, Pugh SL, Klopp AH, Yeung AR, Wenzel L, Westin SN, Gaffney DK, Small W, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Kachnic LA, Bruner DW Tags: Gynecol Oncol Source Type: research

Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
CONCLUSIONS: We showed that patient-derived organoids closely resembled the original gynecologic tumors, and thereby would serve as a promising resource for preclinical studies. PMID: 31101504 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 14, 2019 Category: Cancer & Oncology Authors: Maru Y, Tanaka N, Itami M, Hippo Y Tags: Gynecol Oncol Source Type: research

HPV-prevalence in elderly women in Denmark.
CONCLUSION: Invitation to HPV-screening was well received by elderly women. The HPV-prevalence decreased slightly with increasing age. No rebound of HPV-prevalence after menopause was found when our data were combined with previously published Danish data from younger women. The presently relatively high cervical cancer incidence in elderly women was not reflected in the HPV-prevalence. PMID: 31088688 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 11, 2019 Category: Cancer & Oncology Authors: Andersen B, Christensen BS, Christensen J, Ejersbo D, Heje HN, Jochumsen KM, Johansen T, Larsen LG, Lynge E, Serizawa R, Viborg PH, Waldstrøm M Tags: Gynecol Oncol Source Type: research

Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Abstract OBJECTIVE: To evaluate hematologic adverse effect profiles associated with frontline platinum-based chemotherapy in ovarian cancer patients according to BRCA 1/2 mutational status. METHODS: Patients with high-grade serous ovarian cancer and a known BRCA mutational status who received in frontline 6 cycles of Carboplatin (AUC 5) plus Paclitaxel 175 mg/mq were retrospectively selected from our databases. Hematologic toxicity profiles of BRCA mutated patients were compared to non-mutated patients, according to EORTC Common Terminology Criteria for Adverse Events (CTCAE_4.02). RESULTS: Totally, ...
Source: Gynecologic Oncology - May 9, 2019 Category: Cancer & Oncology Authors: Tomao F, Musacchio L, Di Mauro F, Boccia SM, Di Donato V, Giancotti A, Perniola G, Palaia I, Muzii L, Benedetti Panici P Tags: Gynecol Oncol Source Type: research

Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center.
CONCLUSION: Cytoreductive surgery among older women with advanced OC and frailty can be performed safely in a tertiary care center with preoperative/postoperative geriatric and surgical co-management. PMID: 31078241 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 8, 2019 Category: Cancer & Oncology Authors: Filippova OT, Chi DS, Long Roche K, Sonoda Y, Zivanovic O, Gardner GJ, Tew WP, O'Cearbhaill R, Sarraf S, Sun SW, Alexander K, Korc-Grodzicki B, Shahrokni A Tags: Gynecol Oncol Source Type: research

Association of obesity with survival in patients with endometrial cancer.
Abstract BACKGROUND: Obesity confers an overall increased risk for development of endometrial cancer. However there are conflicting reports regarding the effect of obesity on patients' overall and disease specific survival. The purpose of this study was to evaluate the effect of obesity on survival in women with endometrial cancer. METHODS: After IRB approval, records of women with diagnosis and treatment of endometrial cancer from 1999 to 2016 were abstracted for histopathological, treatment and demographic data. Death was confirmed by query of the Social Security Death Index. Kaplan Meier survival curves an...
Source: Gynecologic Oncology - May 3, 2019 Category: Cancer & Oncology Authors: Van Arsdale A, Miller DT, Kuo DY, Isani S, Sanchez L, Nevadunsky NS Tags: Gynecol Oncol Source Type: research

Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?
CONCLUSIONS: MBO has a relatively poor prognosis. Ovarian and uterine cancer patients whose interventions included surgery or hospice had similar outcomes. Among patients managed medically without hospice, uterine cancer patients experienced worse survival, even when candidates for subsequent chemotherapy. Patient counseling regarding goals of care at this difficult juncture can be informed by these findings and will be enhanced by patient-reported and qualitative data on the patient experience with MBO. PMID: 31056111 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 2, 2019 Category: Cancer & Oncology Authors: Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, Yamada SD Tags: Gynecol Oncol Source Type: research

Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
PMID: 31027611 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 29, 2019 Category: Cancer & Oncology Authors: Ledermann JA Tags: Gynecol Oncol Source Type: research

Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy.
Abstract OBJECTIVE: To analyze our institutional experience and oncologic outcomes for salvage treatment for the recurrence of early-stage endometrial cancer patients. METHODS: We included women of all ages diagnosed with FIGO stage I-II, any grade endometrial cancer from 2000 to 2016 at our institutions who were treated with at least a hysterectomy. Recurrences in the pelvis and/or vagina were considered locoregional recurrences (LRR). Overall survival (OS) was assessed using Kaplan-Meier survival analysis. Univariate (UV) and multivariate (MV) Cox proportional hazards modeling was also used. RESULTS: A...
Source: Gynecologic Oncology - April 24, 2019 Category: Cancer & Oncology Authors: Francis SR, Ager BJ, Do OA, Huang YJ, Soisson AP, Dodson MK, Werner TL, Sause WT, Grant JD, Gaffney DK Tags: Gynecol Oncol Source Type: research

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
aro L, Schettino C, Piccirillo MC, Perrone F, Gallo C, Pignata S Abstract BACKGROUND: Chemotherapy-induced neutropenia (CIN) has been associated with improved prognosis in several cancer conditions. Contrasting data have been produced in ovarian cancer. PMID: 31029508 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 24, 2019 Category: Cancer & Oncology Authors: Daniele G, Arenare L, Scambia G, Pisano C, Sorio R, Breda E, De Placido S, Savarese A, Ferrandina G, Raspagliesi F, Panici PB, Ferro A, Rimanti A, Cormio G, Lorusso D, Cecere SC, Scalone S, Marsico VA, Cardalesi C, Cognetti F, Salutari V, Attademo L, Guiz Tags: Gynecol Oncol Source Type: research

Sentinel lymph nodes (SLN) in endometrial cancer: The relationship between primary tumor histology, SLN metastasis size, and non-sentinel node metastasis.
Abstract OBJECTIVES: To examine sentinel lymph node pathology and describe relationships to uterine pathology, non-sentinel pelvic lymph nodes, and para-aortic lymph nodes. METHODS: Patients with apparent uterine-confined endometrial cancer underwent robotic hysterectomy, SLN mapping, completion pelvic lymphadenectomy (LND), and para-aortic (PaLND) directed by frozen section. Patients were risk stratified by histology: low-risk (LR) endometrioid
Source: Gynecologic Oncology - April 23, 2019 Category: Cancer & Oncology Authors: Kennard JA, Stephens AJ, Ahmad S, Zhu X, Singh C, McKenzie ND, Kendrick JE, Holloway RW Tags: Gynecol Oncol Source Type: research

Lymph node dissection in endometrial cancer and clinical outcome: A population-based study in 5546 patients.
CONCLUSIONS: The application of a risk-adopted management of LND in early endometrial cancer in real-life is associated with a high rate of surgical under- and overtreatment. Corresponding survival data do not show a significant benefit of a systematic lymph node dissection. In order to improve the management and outcome of early endometrial cancer in the future, prospective trials, new surgical concepts and prognostic markers will be primary and necessary. PMID: 31027900 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 23, 2019 Category: Cancer & Oncology Authors: Pölcher M, Rottmann M, Brugger S, Mahner S, Dannecker C, Kiechle M, Brambs C, Grab D, Anthuber C, von Koch F, Schnelzer A, Engel J Tags: Gynecol Oncol Source Type: research

Highlights from the Society of Gynecologic Oncology's 50th Annual Meeting on Women's Cancer.
PMID: 31023555 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 22, 2019 Category: Cancer & Oncology Authors: English DP, Huang M Tags: Gynecol Oncol Source Type: research

Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials.
This study compared treatment outcomes and adverse events in patients with locally advanced cervical cancer undergoing radiotherapy (RT) with concurrent platinum-based doublet therapy vs. RT plus platinum single-agent therapy. The main outcomes were progression-free survival (PFS), overall survival (OS), and the occurrence of adverse events. METHODS: We comprehensively searched Medline, Embase, the Cochrane Library, China National Knowledge Web, Wanfang Database, and VIP database, and performed a systematic review and cumulative meta-analysis of all randomized controlled trials (RCTs) by using the fixed-effect or rand...
Source: Gynecologic Oncology - April 18, 2019 Category: Cancer & Oncology Authors: Ma S, Wang J, Han Y, Guo F, Chen C, Chen X, Zou W Tags: Gynecol Oncol Source Type: research

Obturator nerve regeneration using a genito-femoral graft placed only by fibrin sealant (Tisseel ®).
Obturator nerve regeneration using a genito-femoral graft placed only by fibrin sealant (Tisseel®). Gynecol Oncol. 2019 Apr 17;: Authors: Scaletta G, Bizzarri N, Lauretti L, Scambia G, Fagotti A PMID: 31005285 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 17, 2019 Category: Cancer & Oncology Authors: Scaletta G, Bizzarri N, Lauretti L, Scambia G, Fagotti A Tags: Gynecol Oncol Source Type: research

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
CONCLUSION: mEOC/GOG0241 represents an example of a randomized rare tumor trial. Logistical challenges led to early termination, including difficulties in local histopathological diagnosis and accessing drugs outside their labelled indication. There was misalignment between central funders who support clinical trials in rare cancers and the deprioritisation of such work by those managing and funding research at a local level. Rare cancer trials should include centralised pathology review before treatment. Clinical trial registry number: ISRCTN83438782. PMID: 31005287 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 17, 2019 Category: Cancer & Oncology Authors: Gore M, Hackshaw A, Brady WE, Penson RT, Zaino R, McCluggage WG, Ganesan R, Wilkinson N, Perren T, Montes A, Summers J, Lord R, Dark G, Rustin G, Mackean M, Reed N, Kehoe S, Frumovitz M, Christensen H, Feeney A, Ledermann J, Gershenson DM Tags: Gynecol Oncol Source Type: research

Predictive factors of unexpected lymphatic drainage pathways in early-stage cervical cancer.
ute;curu F Abstract OBJECTIVES: The purpose of this study was to describe sentinel lymph nodes (SLN) topography in patients with early-stage cervical cancer and to determine factors associated with atypical lymphatic drainage pathway (LDP). METHODS: We analyzed the data of two prospective multicentric trials on SLN biopsy for cervical cancer (SENTICOL I and II) in women undergoing surgery for early-stage cervical cancer. SLN detection was realized with a combined labeling technique (Patent blue and radioactive tracer). Patients having bilateral SLN detection were included. Univariate and Multivariate analysis...
Source: Gynecologic Oncology - April 16, 2019 Category: Cancer & Oncology Authors: Balaya V, Mathevet P, Magaud L, Bonsang-Kitzis H, Delomenie M, Montero Macias R, Ngô C, Bats AS, Lécuru F Tags: Gynecol Oncol Source Type: research

Innervation of cervical carcinoma is mediated by cancer-derived exosomes.
CONCLUSIONS: These data identify sensory nerves as components of the cervical cancer microenvironment and suggest that tumor- derived exosomes promote their recruitment. PMID: 31003747 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - April 16, 2019 Category: Cancer & Oncology Authors: Lucido CT, Wynja E, Madeo M, Williamson CS, Schwartz LE, Imblum BA, Drapkin R, Vermeer PD Tags: Gynecol Oncol Source Type: research

Long-term results of fertility-sparing treatment for early-stage cervical cancer.
Abstract OBJECTIVE: To evaluate the long-term outcomes of young early stage cervical cancer patients wishing to preserve their childbearing potential. METHODS: Data of young (aged
Source: Gynecologic Oncology - April 16, 2019 Category: Cancer & Oncology Authors: Bogani G, Chiappa V, Vinti D, Somigliana E, Filippi F, Murru G, Murgia F, Martinelli F, Ditto A, Raspagliesi F Tags: Gynecol Oncol Source Type: research